As the leader in Autologous Biologics, EmCyte Corporation delivers cutting-edge technology that supports evidence-based treatment methodology in the emerging field of regenerative medicine. Our product portfolio meets the highest achievable performance standards at the point of care and contains innovation that improves clinical outcomes for patients around the globe. Offering more power, versatility, efficiency, and quality at the point of care, EmCyte Corporation is committed to the continual development and improvement of devices used for autologous regenerative biologics and to the promotion of autologous therapies used to enhance the quality of life. Our devices are cleared for marketing through both CDRH and CEBR divisions of the FDA, under 510(k) BK050055, K070666, K024080, K183205, and now K191564. EmCyte Corporation has more than 20 years of medical device manufacturing experience, delivering excellence to its customers. At our headquarters in Fort Myers, Florida, we use state-of-the-art manufacturing equipment in a modernized facility housing certified clean rooms to deliver products with the highest safety and quality standards. Our reliable and efficient assembly and packaging operations allow us to develop various custom projects for dedicated customers.